EvolusEOLS
EOLS
About: Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Employees: 372
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
173% more call options, than puts
Call options by funds: $2.18M | Put options by funds: $799K
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
14% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 8 (+1) [Q1 2025]
14% more capital invested
Capital invested by funds: $573M [Q4 2024] → $653M (+$79.8M) [Q1 2025]
9% more funds holding
Funds holding: 164 [Q4 2024] → 179 (+15) [Q1 2025]
3.34% more ownership
Funds ownership: 82.0% [Q4 2024] → 85.34% (+3.34%) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 57
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
111%
upside
Avg. target
$23
135%
upside
High target
$27
172%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger | 122%upside $22 | Buy Reiterated | 8 May 2025 |
BTIG Sam Eiber | 111%upside $21 | Buy Initiated | 17 Apr 2025 |
HC Wainwright & Co. Douglas Tsao | 172%upside $27 | Buy Reiterated | 10 Apr 2025 |
Financial journalist opinion
Based on 5 articles about EOLS published over the past 30 days
Neutral
Business Wire
1 day ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's.
Neutral
Business Wire
4 days ago
Evolysse™ Recognized in 2025 Shape Skin Awards
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program The annual Shape Skin Awards highlight innovation and.
Neutral
Business Wire
2 weeks ago
Evolus Announces Departure of its Chief Financial Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver's resignation is not a result of any disagreement related to the company's operations, policies or practices, including any account.
Neutral
Business Wire
3 weeks ago
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusing on advances in aesthetic medicine and surgery. The multicenter, randomized, controlled, double-blind study followed 140 patients through 12 months and e.
Neutral
Business Wire
4 weeks ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of non-qualified stock options to purchase an aggregate of 12,706 shares of Evolus and an aggregate of 40,576 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's b.
Negative
Zacks Investment Research
1 month ago
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.
Neutral
Seeking Alpha
1 month ago
Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Partners Navann Ty - BNP Paribas Serge Belanger - Needham Doug Tsao - H.C. Wainwright Sam Eiber - BTIG Operator Good afternoon, everyone.
Neutral
Business Wire
1 month ago
Evolus Reports First Quarter 2025 Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2025. “Coming off a record year, we enter 2025 with strong momentum,” said David Moatazedi, President and Chief Executive Officer of Evolus. “In our final quarter as a single-product company, we gained meaningful market share to start the year and delivered.
Neutral
Business Wire
1 month ago
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based.
Negative
Zacks Investment Research
1 month ago
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™